Phosphorylation of PBK at Thr9 by CDK5 correlates with invasion of prolactinomas

Qiuyue Fang,Changxiaofeng Liu,Ding Nie,Jing Guo,Weiyan Xie,Yazhuo Zhang
DOI: https://doi.org/10.1111/cns.14629
2024-02-18
CNS Neuroscience & Therapeutics
Abstract:The level of pPBK‐T9 is highly expressed in invasive PitNETs, CDK5 could promote the phosphorylation of PBK‐T9 through the p38 MAPK signaling pathway to promote cell proliferation and EMT progression. we revealed that this signaling axis in PitNETs, CDK5/PBK/p38 MAPK, promoted the tumorigenesis of PitNETs. Context Prolactinomas are the most prevalent functional pituitary neuroendocrine tumors (PitNETs), and they are invasive to surrounding anatomic structures. The detailed mechanisms of invasion are not yet clear. Objective We explored the role of PBK phosphorylation in the proliferation and invasion of prolactinomas and its possible mechanism. Results We report that PBK directly binds to and is phosphorylated at Thr9 by cyclin‐dependent kinase 5 (CDK5), which promotes GH3 cell EMT progression and proliferation. Phosphorylation of PBK at Thr9 (pPBK‐T9) by CDK5 enhances the stability of PBK. p38 is one of the downstream targets of PBK, and its phosphorylation is reduced as pPBK‐T9 increases in vivo and in vitro. Furthermore, we found that pPBK‐T9 is highly expressed in invasive PitNETs and was significantly correlated with invasion by univariate and multivariate analyses. Conclusions Phosphorylation of PBK at Thr9 by CDK5 promotes cell proliferation and EMT progression in prolactinomas.
pharmacology & pharmacy,neurosciences
What problem does this paper attempt to address?